INNOVATIVE STRATEGY IN THERAPY OF CARDIAC INSUFFICIENCY

Abstract

The article is devoted to the innovative drug to treat chronic cardiac insufficiency – a combination of sakubitril neprilysin inhibitor and first type angiotension II receptor antagonist valsartan (sacubitril/valsartan). Study results are provided in which a combination of sacubitril/valsartan demonstrated effectiveness in patients with arterial hypertension as well as with cardiac insufficiency. Advantages of a combination of sacubitril/valsartan as compared to other drugs affecting components of rennin-angiotension-aldosteron system from the point of view of safety and effectiveness in patients with cardiac insufficiency are demonstrated.

Keywords

• cardiac insufficiency
• rennin-angiotensin-aldosteron system
• neprilysin
• combination sacubitril/valsartan